Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial.
Xu Liu, Liling Xu, Cheng Zhao, Shengyun Liu, Lingyun Sun, Lei Yang, Xiaoyan Xu, Rui Wu, Xiumei Liu, Jing Zhang, Shengqian Xu, Ping Zhu, Haiying Chen, Xiaoxia Wang, Changsong Lin, Jin Lin, Feng Zhan, Hua Wei, Qingchun Huang, Huaxiang Liu, Xinmei Ma, Guixiu Shi, Yuewu Lu, Xiuqin Geng, Zhenyu Jiang, Ning Zhang, Kaijiang Tang, Ronghua Zhang, Yi Zhao, Luan Xue, Shulin Song, Xiaofei Shi, Zhiyi Zhang, Pan Liu, Hui Wang, Zhanguo Li
Arthritis Rheumatol 77(11) 1512-1523
摘要
摘要
OBJECTIVE: This randomized, double-blind, adaptive phase 2/3 trial aimed to evaluate the efficacy and safety of ivarmacitinib, a novel selective JAK1 inhibitor, in patients with active ankylosing spondylitis (AS). METHODS: In phase 2, patients were randomized (1:1:1:1) to receive ivarmacitinib at a dose of 2, 4, or 8 mg or placebo once daily for 12 weeks. Based on interim analysis, ivarmacitinib 4 mg was selected as the recommended dose. In phase 3, patients were randomized (1:1) to receive ivarmacitinib 4 mg or placebo for 12 weeks; from week 12 onward, all patients received ivarmacitinib 4 mg once daily through week 24. The primary end point was the proportion of patients achieving a ≥20% improvement in the Assessment of SpondyloArthritis international Society (ASAS20) response criteria at week 12. RESULTS: During the entire study, 504 patients were randomized (ivarmacitinib 4 mg, n = 187; placebo, n = 186). At week 12, the ASAS20 response rate was significantly higher in the ivarmacitinib 4 mg group compared to the placebo group (48.7% vs 29.0%; one-sided P = 0.0001). The ASAS40 response rate (32.1% vs 18.3%) and all other secondary end points also favored ivarmacitinib 4 mg. Efficacy was sustained through 24 weeks. During the placebo-controlled period, treatment-emergent adverse events occurred in 79.7% of the ivarmacitinib group and 65.6% of the placebo group. CONCLUSION: Ivarmacitinib 4 mg significantly improved the signs and symptoms of AS at week 12 compared to placebo, with sustained efficacy through 24 weeks and a tolerable safety profile. These findings support ivarmacitinib 4 mg as a new treatment option for active AS.
KM 提取结果
0 个 Figure · 0 个 KM 面板